feburic是非布司他吗？

The Chinese name is febuxostat, which is a selective inhibitor of non-purine xanthine oxidase/xanthine dehydrogenase. It works by reducing blood urate concentration. Unlike allopurinol, its structure is a non-purine analogue, so it is selective for the inhibition of xanthine oxidase and other enzymes in purine or pyrimidine metabolism (such as guanine deamination). Enzyme pyrimidine nucleoside phosphorylase, purine nucleoside phosphorylase, etc.) has a very small effect, while allopurinol is a purine analogue, which can affect the activity of other enzymes in purine and pyrimidine metabolism in the body, and is prone to some adverse reactions. The specificity of febuxostat's inhibitory effect can avoid these possible adverse reactions, and it is clinically used to reduce blood uric acid in patients with gout.

The starting dose of febuxostat is 40 mg once daily. If the blood uric acid level is still not less than 6 mg/dl (approximately 360 μmol/L) after 2 weeks, it is recommended that the dose be increased to 80 mg once a day. Food and antacid effects do not need to be considered when administering the drug. Patients with mild or moderate hepatic insufficiency (Child-Pugh classes A and B) do not need to adjust the dosage. Patients with severe hepatic insufficiency (Child-Pugh class C) should use febuxostat with caution.

Medication for pregnant and lactating women:

There are no sufficient controlled studies in pregnant women, and in animal experiments it was found that febuxostat can be excreted through breast milk, but it has not been determined whether it will be excreted through human milk. Therefore, pregnant and lactating women should use this drug with caution.

Medication for children:

There have been no studies using febuxostat in pediatric patients.

Medication for elderly patients:

Clinical studies have shown that after multiple oral administrations of febuxostat to elderly subjects, Cmax and AUC24 are similar to those of young subjects, so there is no need to adjust the dose in the elderly.

Adverse reactions:

1. Abnormal liver function, nausea, joint pain, rash, diarrhea and dizziness, among which abnormal liver function is a serious adverse reaction.

2. Some literature reports that common adverse reactions include upper respiratory tract infection, muscle and skeletal muscle and related tissue abnormalities, headache, edema, pulmonary infection, abnormal sensation and hypoesthesia, etc.

3. The incidence of serious adverse reactions is cardiovascular disease, including non-fatal myocardial infarction, non-fatal stroke and cardiovascular death, which is higher than that of allopurinol. The incidence of cardiovascular adverse reactions is not related to the dose of (febuxostat) and does not increase with the extension of treatment time.